HFSA Heart Failure Seminar: Focus on Guideline-Directed Medical Therapy (GDMT)Everything you want to know, and not afraid to ask: The evidence, the how, and the challenges.Original Seminar Date: April 22,2022Product Expiration Date: May 6, 2023The optimization of GDMT in the treatment of HF has been shown to reduce morbidity and mortality and improve patient outcomes. However, many HF patients do not receive GDMT and/or achieve the recommended target dose of their medications. Studies have shown that while most patients are managed by cardiologists or primary care practitioners, GDMT and target doses of medication can also be successfully achieved by expanding this role to other providers. Education on GDMT, optimizing medications, and these successful strategies are needed to expand patient outcomes. This program will provide practitioners with updated information on the universal definition of heart failure, guideline-directed medical therapies (GDMT), and strategies that optimize medical therapies (OMT) to improve patient outcomes.
This program is intended for physicians, nurses, nurse practitioners, physician assistants, and advanced practice professionals that provide care to patients with heart failure.
At the conclusion of this activity, learners will be better able to:
Freny Vaghaiwalla Mody, MDProfessor of MedicineDavid Geffen School of Medicine at UCLADirector, Heart Failure Program & Preventive Cardiology ProgramVeterans Administration of Greater Los Angeles Health Care System, Los Angeles, CADisclosure(s): Nothing to DiscloseJanet Crawford, APRN, DNP, MBA, MSN, ACNP-BC, FNPOrlando Health Heart and Vascular Institute, Orlando, FLDisclosure(s): Nothing to DiscloseCourtney Shakowski, PharmD, FHFSAClinical Assistant ProfessorUniversity of Colorado School of PharmacyClinical Pharmacy Specialist – Critical Care / CardiologyUniversity of Colorado Hospital, Aurora, CODisclosure(s): Nothing to Disclose
Larry A. Allen, MD, MHSProfessor of Medicine, Kenneth Poirier Endowed ChairAssociate Head for Clinical Affairs, CardiologyMedical Director, Advanced Heart FailureUniversity of Colorado, School of Medicine, Aurora, CODisclosure(s): Consultant: ACI Clinical, Boston Scientific, Novartis, and Cytokinetics, Inc.Robert L Page II, PharmD, MSPH, FHFSAProfessor of Clinical PharmacyUniversity of Colorado Skaggs School of PharmacyClinical Specialist, Division of CardiologyUniversity of Colorado Health System, Aurora, CODisclosure(s): Nothing to DiscloseLynne Warner Stevenson, MD, FHFSALisa M. Jacobson Professor of Cardiovascular Medicine and Director of CardiomyopathyVanderbilt University School of Medicine, Nashville, TNDisclosure(s): Nothing to Disclose
Welcome and IntroductionFreny Vaghaiwalla Mody, MDJanet Crawford, APRN, DNP, MBA, MSN, ACNP-BC, FNPCourtney Shakowski, PharmD, FHFSA
Guideline-Directed Medical Therapy (GDMT): Evidence and Benefits and Live Q&ALarry A. Allen, MD, MHSTearing Down the Barriers to Optimizing GDMT: Considerations in the Patient with Heart Failure and Live Q&ARobert L Page II, PharmD, MSPH, FHFSAPersonalizing Therapy for the Tough Cases and Strategies for Navigating Comorbidities Which Become Barriers to Success and Live Q&ALynne Warner Stevenson, MD, FHFSA
Panel DiscussionFaculty
In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum 1.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE.
ACPE Universal Activity Number (UAN): JA4008267-0000-22-001-L04-P
The Heart Failure Society of America acknowledges Merck for providing an unrestricted educational grant to support the Heart Failure Seminar: Focus on Guideline-Directed Medical Therapy (GDMT).